Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 193

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 193
---
 of the Indirect JCP Reporting Persons disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the common stock held directly by JCP III AIV in which the Indirect Reporting Persons have no pecuniary interest. |

Amount consists of (1) 568,990 shares of common stock held by JCP III AIV, (2) 1,365 shares of common stock held by METP, and (3) 214,614 shares of common stock underlying warrants held by JCP III AIV that were exercisable as of February 13, 2025, or will be exercisable within 60 days thereafter.

| (4) | Amount consists of (1) 13,347 shares of common stock and (2) 84,000 shares of common stock underlying stock options held by Mr. Bernstein that were vested as of February 13, 2025 or will vest within 60 days thereafter. |

| (5) | Amount consists of (1) 16,238 shares of common stock and (2) 84,000 shares of common stock underlying stock options held by Mr. Silverman that were vested as of February 13, 2025 or will vest within 60 days thereafter. |

| (6) | Amount consists of (1) 13,315 shares of common stock and (2) 84,000 shares of common stock underlying stock options held by Mr. Walker that were vested as of February 13, 2025 or will vest within 60 days thereafter. |

| (7) | Amount consists of (i) 76,100 shares of common stock underlying stock options held by Mr. Boctor that were vested as of February 13, 2025 or will vest within 60 days thereafter and (ii) 49,645 shares of common stock underlying certain restricted stock units that were vested as of February 13, 2025 or will vest within 60 days thereafter. |

| (8) | Amount consists of (1) 117 shares of common stock held directly and (2) 25,000 shares of common stock underlying stock options held by Mr. Arnold that were vested as of February 13, 2025 or will vest within 60 days thereafter. |

115

<div align='center'>EXPERTS</div>

The consolidated financial statements of Petros Pharmaceuticals, Inc. as of and for the year ended December